Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)

EQS-News: Formycon AG


/ Key word: Market Launch





Formycon announces commercial launch of FYB201 in Canada and Switzerland






11.04.2024 / 07:30 CET/CEST



The issuer is...

Related Keywords

Munich ,Bayern ,Germany ,Canada ,Australia ,United Kingdom ,United States ,Japan ,Switzerland ,Frankfurt ,Brandenburg ,Swiss ,British ,America ,Canadian ,Larissa Moniz ,Nicola Mikulcik ,Jennifer Pereira ,Teva Pharmaceutical Industries Ltd ,Health Canada ,Teva Pharmaceuticals ,Polpharma Biologics Group ,Frankfurt Stock Exchange ,Genentech Inc ,Teva Canada ,Investor Relations Corporate Communications ,North America ,Pharmaceutical Industries ,Investor Relations ,Corporate Communications ,British Journal ,Chad Andrews ,Meeting Abstract ,Markets ,